Floatz logo

TRASTUZUMAB

Cancer Related Cognitive Decline

Georgetown Universitymonoclonal_antibodyPhase 1/2Active
CCC
48/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
95/ 100

Competitive context

6 Active assets in the Cancer Related Cognitive Decline cohort.

Asset / SponsorPhaseRating
Cyclophosphamide
Georgetown University
Phase 1/2CCC
Carboplatin
Georgetown University
Phase 1/2CCC
Azeliragon
Georgetown University
Phase 1/2CCC
IMMUNOGLOBULIN G1, ANTI-(HUMAN NEU (RECEPTOR)) (HUMAN-MOUSE MONOCLONAL 2C4 HEAVY CHAIN), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL 2C4 .KAPPA.-CHAIN, DIMER
Georgetown University
Phase 1/2CCC
Docetaxel
Georgetown University
Phase 1/2CCC
Inno-206
Georgetown University
Phase 1/2CCC

Same molecule, other indications

TRASTUZUMAB is also rated in:

breast carcinomaDormant
BBB
Indicative ·
76 / 100
View asset →
inflammatory breast carcinomaDormant
BBB
Indicative ·
74 / 100
View asset →
HER2/Neu PositiveDormant
BBB
Indicative ·
74 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →